Onkológia 6/2023

Daratumumab across multiple myeloma treatment lines

Despite advances in treatment, multiple myeloma remains an incurable disease, highlighting the need for new, more effective treatment strategies. The discovery of the monoclonal antibody daratumumab has improved treatment outcomes for these patients in recent years. The unique multifaceted mechanism of action of daratumumab has led to great success in the treatment of patients with relapsed refractory multiple myeloma as well as newly diagnosed multiple myeloma. The advantage of its use is the low toxicity profile, which was further improved by the introduction of subcutaneous daratumumab into clinical practice. This article reviews the development of daratumumab, its practical use and current indications.

Keywords: daratumumab, monoclonal antibody, newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma